Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-046-9 | CAS number: 91-17-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- sub-chronic toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1996-09-16 to 1996-12-18
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Comparable to Guideline study
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 2 005
Materials and methods
- Principles of method if other than guideline:
- Repeated Dose Toxicity, U.S. NTP
- GLP compliance:
- no
- Limit test:
- no
Test material
- Reference substance name:
- Decahydronaphthalene
- EC Number:
- 202-046-9
- EC Name:
- Decahydronaphthalene
- Cas Number:
- 91-17-8
- Molecular formula:
- C10H18
- IUPAC Name:
- decahydronaphthalene
- Details on test material:
- Decahydronaphthalene, mixed lots 07347LG and 12426EN of Sigma Aldrich Fluka Bulk Chemicals (St. Louis, MO, USA), purity > 99 %
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Fischer 344
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ORGANISMS
- Source: Taconic Laboratory Animals and Services, Germantown (NY, USA)
- Age: 6 weeks at study initiation
- Weight at study initiation: males mean 97 g, females mean 90 g (core study)
Number of animals: total 25 males + 20 females per exposure concentration
- Food a(d libitum except during exposure and urine collection periods), irradiated: NTP-2000 open formula pelleted diet (Zeigler Brothers, Inc., Gardners, PA)
- Water (ad libitum): tap water
- Housing: individually in Stainless-steel wire bottom (Hazleton System, Inc., Aberdeen, MD)
ENVIRONMENTAL CONDITIONS (CHAMBER)
- Temperature: 72° ± 3° F
- Relative humidity: 50% ± 15%
- Room fluorescent light: 12 hours/day
- Chamber air changes: 15/hour
Administration / exposure
- Route of administration:
- inhalation: vapour
- Type of inhalation exposure:
- whole body
- Vehicle:
- other: clean air
- Details on inhalation exposure:
- ADMINISTRATION / EXPOSURE
- Duration of exposure:
2 weeks: 5 male renal toxicity rats
6 weeks: 10 male + 10 female clinical pathology rats
14 weeks: 10 male + 10 female core study rats
- Type of exposure: whole-body inhalation
- Vehicle: clean air
- Concentration in vehicle: established within 12 minutes, monitored every 24 minutes At 72 +- 3 °F (22.2 °C) the ppm concentrations
correspond to: 143, 285, 570, 1141, 2282 mg/m3 - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Concentrations in the exposure chambers were monitored every 24 minutes by an on-line gas chromatograph
- Duration of treatment / exposure:
- 2, 6, or 14 weeks; 1 additional day before end of study
- Frequency of treatment:
- 6 hours (+ 12 minutes concentration buildup)/day, 5 days/week
Doses / concentrations
- Remarks:
- Doses / Concentrations:
25, 50, 100, 200, 400 ppm
Basis: analytical conc.
- No. of animals per sex per dose:
- 25 male and 20 female rats
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Post-exposure period: none
Examinations
- Observations and examinations performed and frequency:
- CLINICAL OBSERVATIONS AND FREQUENCY:
- Clinical signs: observed twice daily
- Mortality: observed twice daily
- Clinical findings: weekly
- Body weight: initially, weekly, end of study
- Hematology: Blood sampling on days 3 and 23 (clinical pathology group) or at end of study (core
study group). Determination of hematocrit; packed red cell volume; hemoglobin; erthrocyte, reticulocyte, nucleated erythrocyte, and platelet counts; mean cell volume; mean cell hemoglobin; mean cell hemoglobin concentration; and leukocyte count and differentials
- Biochemistry: Urea nitrogen, creatinine, total protein, albumin, globulin, albumin/globulin ratio, alanine aminotransferase, alkaline phosphatase, creatine kinase, sorbitol dehydrogenase, and bile acids
- Urinalysis: sampling during week 12. Determination of creatinine, glucose, glucose/creatinine ratio, protein, protein/creatinine ratio, alkaline phosphatase, alkaline phosphatase/creatinine ratio, alkaline aminotransferase, aspartate aminotransferase, aspartate aminotransferase/creatinine ratio, lactate dehydrogenase, lactate dehydrogenase/creatinine ratio, gamma-glutamyltransferase, gamma-glutamyltransferase/creatinine ratio, N-acetyl-beta-D-glucosaminidase, N-acetyl-beta-D-glucosaminidase/creatinine ratio, volume, and specific gravity
OTHER EXAMINATIONS:
- Sperm motility: Collection of sperm samples from 0, 100, 200, and 400 ppm males at the end of the study. Evaluation of: spermatid heads per
testis, per gram testis, per cauda, and per gram cauda and epididymal spermatozoal motility. The left cauda, left epididymis, and left testis were
weighed.
- Vaginal cytology: Collection of vaginal samples for up to 12 consecutive days prior to the end of the study from 0, 100, 200, or 400 ppm females.
The percentage of time spent in the various estrous cycle stages and estrous cycle length were evaluated.
- Renal effects: 16 hour-urine samples (all exposure concentrations) from
- 2 weeks: 5 male renal toxicity + 5 female clinical pathology rats: volume and decalol excretion;
- 6 weeks: 5 male + 5 female clinical pathology rats: volume and decalol excretion;
- 12 weeks:10 male + 10 female core study rats: volume.
Urine analysis (all exposure groups) for
- weeks 2 and 6: decalol and creatinine
- week 12: creatinine Right kidney sample analysis (all male groups) for
- weeks 2, 6, and 14: cis- and trans-decahydronaphthalene, cis- and trans-decahydro-2-naphthalone, a2u-globulin Right kidney sample analysis
(females) for
- week 14: cis- and trans-decahydronaphthalene Calculation of several concentration ratios.
- Assessment of cell proliferation: Analysis of left kidney sections and duodenum from
- 5 male renal toxicity rats (2 weeks),
- 5 male clinical pathology rats (6 weeks),
- 5 or 10 male core study rats (14 weeks) - Sacrifice and pathology:
- SACRIFICE
Carbon dioxide asphyxiation
PATHOLOGY
Necropsy was performed on all core study animals. Organs weighed were the heart, right kidney, liver, lung, right testis, and thymus.
- Weights: heart, right kidney, liver, lung, right testis, thymus
- Macroscopic: yes, no details reported
- Microscopic: 0 and 400 ppm core study rats: gross lesions, adrenal gland, bone with marrow, brain, clitoral gland, esophagus, heart, large intestine (cecum, colon, rectum), small intestine (duodenum, jejunum, ileum), kidney, larynx, liver, lung, lymph nodes (mandibular, mesenteric, bronchial, and mediastinal), mamary gland, nose, ovary, pancreas, parathyroid gland, pituitary gland, preputial gland, prostate gland, salivary gland, skin, spleen, stomach (forestomach and glandular), testis with epididymis and semial vesicle, thymus, thyroid gland, trachea, urinary bladder, and uterus
Other groups: kidney of male rats. - Statistics:
- STATISTICAL METHODS: not specifically reported; general data compiled with carcinogenicity study data in chapter 5.7
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- There were no clinical findings related to exposure.
- Mortality:
- no mortality observed
- Description (incidence):
- All rats survived to the end of the study.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Mean body weights of exposed groups were similar to those of the control groups.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- Several transient observations were minimal and not considered toxicologically relevant
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- Several transient observations were minimal and not considered toxicologically relevant
- Urinalysis findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Significant findings were consistent with the renal toxicity data and the renal lesions observed microscopically:
increase in glucose/creatinine ratio (males >= 25 ppm: 20-93 %)
increase in protein/creatinine ratio (males >= 25 ppm: 19-44 %)
increase in aspartate aminotransferase/creatinine ratio (males >= 25 ppm: 4.9-6.7fold, females >= 50 ppm: 1.7-2.3fold)
increase in lactate dehydrogenase/creatinine ratio (males and females >= 25 ppm: 3.0-4.2fold and 1.5-2.1fold, respetively) - Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Absolute and/or relative kidney and liver weights of male rats exposed to >= 50 ppm were increased, s. "Any other information on results incl. tables"
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Incidences and/or severities of hyaline droplet accumulation and renal tubule regeneration in the kidney generally increased with increasing exposure concentration. Granular casts were seen in the kidney at 6 weeks and at terminal sacrifice.
- Histopathological findings: neoplastic:
- no effects observed
- Description (incidence and severity):
- Concentrations of a2u-globulin in the kidney as well as the a2u globulin/soluble protein ratios were significantly increased in the 200 and 400 ppm males at weeks 2, 6, and 14. Sperm motility and vaginal cytology parameters were not affected by exposure.
Effect levels
open allclose all
- Key result
- Dose descriptor:
- NOAEC
- Effect level:
- 25 ppm
- Based on:
- act. ingr.
- Sex:
- male/female
- Basis for effect level:
- urinalysis
- Dose descriptor:
- LOAEC
- Effect level:
- > 25 ppm
- Sex:
- male/female
- Basis for effect level:
- other: see 'Remark'
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Concentration | Kidney | Liver | ||
absolute | relative | absolute | relative | |
25 ppm | +5.8 % | +4.5 % * | +5.5 % | +3.9 % |
50 ppm | +5.3 % | +7.9 % ** | +5.1 % | +8.0 % ** |
100 ppm | +3.3 % | +7.7 % ** | +1.2 % | +5.5 % ** |
200 ppm | +15.0 % ** | +11.5 % ** | +12.1 % ** | +8.7 % ** |
400 ppm | +19.8 % ** | +19.6 % ** | +11.2 % ** | +10.9 % ** |
Applicant's summary and conclusion
- Conclusions:
- Urinalysis showed significant findings (increase in lactate dehydrogenase/creatinine ratio and in aspartate aminotransferase/creatinine ratio) in male and female rats exposed to 25 ppm and greater. Absolute and/or relative kidney and liver weights of male rats exposed to 50 ppm were increased. Females were not affected. So the changes in enzyme urine levels in female rats are not adverse effects, because they are not related to any simultaneous increase of kidney weight damage and therefore, 25 ppm is determined to be the no observed effect concentration (NOAEC) in female rats in this 90 day study.
Furthermore, Decahydronaphthalene causes male rat-specific alpha2u-globulin nephropathy. This type of kidney toxicity characterised by increased formation of hyaline droplets, increased concentration of alpha2u-globulin results in increased cell proliferation and may increase renal adenoma and carcinoma rates. Because the mechanism has been established as species and sex-specific for the male rat it is generally considered to be of no relevance for human health, endpoints resulting from male nephrotoxicity are not considered as relevant. - Executive summary:
Groups of 25 male and 20 female F344/N rats were exposed to 0, 25, 50, 100, 200, or 400 ppm decalin vapor 6 hours per day, 5 days per week for 2 (five male renal toxicity rats), 6 (10 male and 10 female clinical pathology rats), or 14 (10 core study rats) weeks. All rats survived to the end of the study, and mean body weights of exposed groups were similar to those of the chamber control groups. Urinalysis results indicated that decalin exposure caused increases in urine glucose and protein concentrations and enzyme activities that were consistent with the renal lesions observed microscopically. Renal toxicity studies were performed on rats sacrificed at 2 and 6 weeks and at the end of the study. In kidney tissue examined for cell proliferation, the numbers of PCNA-labeled cells and labeling indices were generally significantly greater than those of the chamber controls in exposed groups of rats at all three time points. Concentrations of alpha2u-globulin in the kidney as well as the alpha2u-globulin/soluble protein ratios were significantly increased at week 2 in all exposed groups and in the 200 and 400 ppm groups at week 6 and at the end of the study. Absolute and/or relative kidney and liver weights of male rats exposed to 50 ppm or greater were increased. Females were not affected. Incidences of renal tubule regeneration and granular casts in the medulla of the kidney in exposed male rats were increased, and the severities of hyaline droplets generally increased with increasing exposure concentration.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.